SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    American Cancer Society. Cancer facts and figures. Atlanta, GA: American Cancer Society, 2004.
  • 2
    Gambhir SS, Czermin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med. 2001; 42: 1S93S.
  • 3
    Czermin J, Phelps M. Positron emission tomography scanning: current and future applications. Annu Rev Med. 2002; 53: 89112.
  • 4
    Freudenberg LS, Antoch G, Schütt P, et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging. 2004; 31: 325329.
  • 5
    Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer. 2004; 90: 620625.
  • 6
    Filmont JE, Vranjesevic D, Quon A, et al. Conventional imaging and 2-deoxy-2[18F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of previously treated non-Hodgkin's lymphoma patients. Mol Imaging Biol. 2003; 5: 232239.
  • 7
    Hong SP, Han JS, Lee JD, Bae SW, Youn MJ. 18F-fluorodeoxyglucose-positron emission tomography in the staging of malignant lymphoma compared with CT and 67Ga scan. Yonsei Med J. 2003; 44: 779786.
  • 8
    Schöder H, Meta J, Yap C, et al. Effect of whole-body 18F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med. 2001; 42: 11391143.
  • 9
    Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small cell lung cancer. A meta-analysis. Ann Intern Med. 2003; 139: 879892.
  • 10
    Schelbert HR, Hoh CK, Royal HD, et al. Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine. J Nucl Med. 1998; 39: 13021305.
  • 11
    Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data analytic approaches and some additional considerations. Stat Med. 1993; 12: 12931316.
  • 12
    Zhou XH, McClish DK, Obuchowski NA. Statistical methods in diagnostic medicine. New York: Wiley Interscience 2002: 222240.
  • 13
    StataCorp. Stata statistical software: release 7.0. College Station, TX: StataCorp, 2001.
  • 14
    Najjar F, Hustinx R, Jerusalem G, Fillet G, Rigo P. Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL). Cancer Biother Radiopharm. 2001; 16: 297304.
  • 15
    Shen YY, Kao A, Yen RF. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma. Oncol Rep. 2002; 9: 321325.
  • 16
    Weihrauch MR, Re D, Bischoff S, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol. 2002; 81: 2025.
  • 17
    Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 2001; 86: 266273.
  • 18
    Tatsumi M, Kitayama H, Sugahara H, et al. Whole-body hybrid PET with 18F-FDG in the staging of non-Hodgkin's lymphoma. J Nucl Med. 2001; 42: 601608.
  • 19
    Jerusalem G, Warland V, Najjar F, et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun. 1999; 20: 1320.
  • 20
    Wirth A, Seymour JF, Hicks RJ, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, Gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med. 2002; 12: 262268.
  • 21
    Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology. 1997; 203: 795800.
  • 22
    Hoh CK, Glaspy J, Rosen P, et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med. 1997; 38: 343348.
  • 23
    Hoffman M, Kletter K, Becherer A, Jäger U, Chott A, Raderer M. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology. 2003; 64: 336340.
  • 24
    Weidmann E, Baican B, Hertel A, et al. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. Leuk Lymphoma. 1999; 34: 545551.
  • 25
    Delbeke D, Martin WH, Morgan DS, et al. 2-deoxy-2-[F-18]fluoro-D-glucose imaging with positron emission tomography for initial staging of Hodgkin's disease and lymphoma. Mol Imaging Biol. 2002; 4: 105114.
  • 26
    Partridge S, Timothy A, O'Doherty MJ, Hain SF, Rankin S, Mikhaeel G. 2-fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol. 2000; 11: 12731279.
  • 27
    Jerusalem G, Beguin Y, Najjar F, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol. 2001; 12: 825830.
  • 28
    Montravers F, McNamara D, Landman-Parker J, et al. [18F]FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med. 2002; 29: 11551165.
  • 29
    Rini JN, Leonidas JC, Tomas MB, Palestro CJ. 18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma. J Nucl Med. 2003; 44: 10721074.
  • 30
    Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer. 2002; 94: 879888.
  • 31
    Rini JN, Manalili EY, Hoffman MA, et al. F-18 FDG versus Ga-67 for detecting splenic involvement in Hodgkin's disease. Clin Nucl Med. 2002; 27: 572577.
  • 32
    Hwang K, Park CH, Kim HC, et al. Imaging of malignant lymphomas with F-18 FDG coincidence detection positron emission tomography. Clin Nucl Med. 2000; 25: 789795.
  • 33
    Bar-Shalom R, Yefremov N, Haim N, et al. Camera-based FDG PET and 67Ga SPECT in evaluation of lymphoma: comparative study. Radiology. 2003; 277: 353360.
  • 34
    Jerusalem G, Beguin Y, Fassone MF, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol. 2003; 14: 123130.
  • 35
    Kotzerke J, Guhlmann A, Moog F, Frickhofen N, Reske SN. Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma. Eur J Nucl Med. 1999; 26: 3138.
  • 36
    Zinzani PL, Chierichietti F, Zompatori M, et al. Advantages of positron emission tomography (PET) with respect to computed tomography in the follow-up of lymphoma patients with abdominal presentation. Leuk Lymphoma. 2002; 43: 12391243.
  • 37
    Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood. 2003; 101: 38753876.
  • 38
    de Wit M, Bumann D, Beyer W, Herbst K, Clausen M, Hossfeld DK. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol. 1997; 8: S57S60.
  • 39
    Spaepen K, Stroobans S, Dupont P, et al. Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002; 13: 13561363.
  • 40
    Van den Bossche, Lambert B, de Winter F, et al. FDG-PET versus high dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients. Nucl Med Commun. 2002; 23: 10791083.
  • 41
    Bangerter M, Moog F, Buchmann I, et al. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol. 1998; 9: 11171122.
  • 42
    Moog F, Kotzerke J, Reske SN. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med. 1999; 40: 14071413.
  • 43
    Lang O, Bihl H, Hültenschmidt B, Sautter-Bihl ML. Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin's disease. Strahlenther Onkol. 2001; 177: 138144.
  • 44
    Stumpe KDM, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med. 1998; 25: 721728.
  • 45
    Mikosch P, Gallowitsch HJ, Zinke-Cerwenka W, et al. Accuracy of whole-body 18F-FDP-PET for re-staging malignant lymphoma. Acta Med Austriaca. 2003; 30: 4147.
  • 46
    Hüeltenschmidt B, Sautter-Bihl ML, Lang O, et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer. 2001; 91: 302310.
  • 47
    Rodriguez M, Ahlström H, Sundín A, et al. [18F] FDG PET in gastric non-Hodgkin's lymphoma. Acta Oncol. 1997; 36: 577584.
  • 48
    Blum RH, Seymour JF, Wirth A, MacManus M, Hicks RJ. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma. 2003; 4: 4349.
  • 49
    Horwitz MD, Horning S. Advances in the treatment of Hodgkin's lymphoma. Curr Opin Hematol. 2000; 7: 235240.
  • 50
    Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998; 339: 2126.
  • 51
    Irwig L, Macaskill P, Glasziou P, et al. Meta-analytic methods for diagnostic test accuracy. J Clin Epidemiol. 1995; 48: 119130.
  • 52
    Lijmer J, Bossuyt PM, Heisterkamp SH. Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat Med. 2002; 21: 15251537.
  • 53
    Thompson SG. Systematic review: why sources of heterogeneity in meta-analysis should be investigated. BMJ. 1994; 309: 13511355.
  • 54
    Gould MK, Maclean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA. 2001; 285: 914924.
  • 55
    Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s–meta-analytic comparison of PET and CT. Radiology. 1999; 213: 530536.
  • 56
    Huebner RH, Park KC, Sheperd JE, et al. A meta-analysis of the literature for whole body FDG PET detection of recurrent colorectal cancer. J Nucl Med. 2000; 41: 11771189.
  • 57
    Kinkel K, Lu Y, Both M, et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR Imaging, PET): a meta-analysis. Radiology. 2002; 224: 748756.
  • 58
    Cremerius U, Fabry U, Neueerburg J, Zimny M, Osieka R, Buell U. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun. 1998; 19: 10551063.
  • 59
    Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol. 1998; 16: 603609.
  • 60
    Bangerter M, Kotzerke J, Griesshammer M, Eisner K, Reske SN, Bergmann L. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol. 1999; 38: 799804.
  • 61
    Moog F, Bangerter M, Diederichs CG. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology. 1998; 206: 475481.
  • 62
    Sutinen E, Jyrkkiö S, Varpula M, et al. Nodal staging of lymphoma with whole-body PET: comparison of [11C]Methionine and FDG. J Nucl Med. 2000; 41: 19801988.
  • 63
    Buchmann I, Reinhart M, Eisner K, et al. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. Cancer. 2001; 91: 889899.
  • 64
    Menzel C, Döbert N, Mitrou P. Positron emission tomography for the staging of Hodgkin's lymphoma. Acta Oncol. 2002; 41: 430436.
  • 65
    Sasaki M, Kuwabara Y, Koga H, et al. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. Ann Nucl Med. 2002; 16: 337345.